nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.11.2012 | Original article

Prognostic value of HIF-1α expression during fractionated irradiation

verfasst von: L. Helbig, A. Yaromina, S.N. Sriramareddy, S. Böke, L. Koi, H. D. Thames, M. Baumann, Prof. Dr. D. Zips

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Hypoxia and reoxygenation are important determinants of outcome after radiotherapy. HIF-1α is a key molecule involved in cellular response to hypoxia. HIF-1α expression levels have been shown to change after irradiation. The objective of the present study was to explore the prognostic value of HIF-1α expression during fractionated irradiation.

Materials and methods

Six human squamous cell carcinoma models xenografted in nude mice were analysed. Tumours were excised after 3, 5 and 10 fractions. HIF-1α expression was quantified by western blot. For comparative analysis, previously published data on local tumour control data and pimonidazole hypoxic fraction was used.

Results

HIF-1α expression in untreated tumours exhibited intertumoural heterogeneity and did not correlate with pimonidazole hypoxic fraction. During fractionated irradiation the majority of tumour models exhibited a decrease in HIF-1α expression, whereas in UT-SCC-5 no change was observed. Neither kinetics nor expression levels during fractionated irradiation correlated with local tumour control.

Conclusion

Our data do not support the use of HIF-1α determined during treatment as a biomarker to predict outcome after fractionated irradiation.

Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916PubMed

Bache M, Kappler M, Said HM et al (2008) Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 15:322–338PubMedCrossRef

Bayer C, Shi K, Astner ST et al (2011) Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 80:965–968PubMedCrossRef

Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425–437PubMedCrossRef

Harada H, Itasaka S, Zhu Y et al (2009) Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 100:747–757PubMedCrossRef

Horsman M, Wouters BG, Joiner MC, Overgaard J (2009) The oxygen effect and fractionated radiotherapy. In: Joiner MC, Van der Kogel A (eds) Basic clinical radiobiology. 4th ed. Arnold, London, pp 207–216

Hui EP, Chan AT, Pezzella F et al (2002) Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595–2604PubMed

Janssen HL, Haustermans KM, Sprong D et al (2002) HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54:1537–1549PubMedCrossRef

Kappler M, Taubert H, Holzhausen HJ et al (2008) Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol 184:393–399PubMedCrossRef

10.

Kappler MA (2008) Software for rapid prototyping in the pharmaceutical and biotechnology industries. Curr Opin Drug Discov Devel 11:389–392PubMed

11.

Kessler J, Hahnel A, Wichmann H et al (2010) HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer 10:605PubMedCrossRef

12.

Koukourakis MI, Giatromanolaki A, Danielidis V, Sivridis E (2008) Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol 84:47–52PubMedCrossRef

13.

Koukourakis MI, Giatromanolaki A, Sivridis E et al (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192–1202PubMedCrossRef

14.

Li F, Sonveaux P, Rabbani ZN et al (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26:63–74PubMedCrossRef

15.

Mayer A, Hockel M, Wree A et al (2008) Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res 68:4719–4726PubMedCrossRef

16.

Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441PubMedCrossRef

17.

Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99–110PubMedCrossRef

18.

Rademakers SE, Lok J, Kogel AJ van der et al (2011) Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11:167PubMedCrossRef

19.

Schilling D, Bayer C, Emmerich K et al (2012) Basal HIF-1alpha expression levels are not predictive for radiosensitivity of human cancer cell lines. Strahlenther Onkol 188:353–358PubMedCrossRef

20.

Schilling D, Bayer C, Li W et al (2012) Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1alpha. PLoS One 7:e31110PubMedCrossRef

21.

Schutze C, Bergmann R, Yaromina A et al (2007) Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol 83:311–315PubMedCrossRef

22.

Schwartz DL, Powis G, Thitai-Kumar A et al (2009) The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 8:947–958PubMedCrossRef

23.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732PubMedCrossRef

24.

Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625–634PubMedCrossRef

25.

Silva P, Slevin NJ, Sloan P et al (2008) Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol Biol Phys 72:1551–1559PubMedCrossRef

26.

Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 65:7259–7266PubMedCrossRef

27.

Staab A, Fleischer M, Loeffler J et al (2011) Small interfering RNA targeting HIF-1alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 187:252–259PubMedCrossRef

28.

Broek GB van den, Wildeman M, Rasch CR et al (2009) Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124:2643–2650PubMedCrossRef

29.

Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239PubMedCrossRef

30.

Vordermark D, Brown JM (2003) Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int J Radiat Oncol Biol Phys 56:1184–1193PubMedCrossRef

31.

Vordermark D, Katzer A, Baier K et al (2004) Cell type-specific association of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein accumulation and radiobiologic tumor hypoxia. Int J Radiat Oncol Biol Phys 58:1242–1250PubMedCrossRef

32.

Williams KJ, Telfer BA, Xenaki D et al (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75:89–98PubMedCrossRef

33.

Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8:851–864PubMedCrossRef

34.

Xueguan L, Xiaoshen W, Yongsheng Z et al (2008) Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol) 20:606–612

35.

Yaromina A, Eckardt A, Zips D et al (2009) Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. Radiother Oncol 92:460–465PubMedCrossRef

36.

Yaromina A, Krause M, Thames H et al (2007) Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 83:304–310PubMedCrossRef

37.

Yaromina A, Kroeber T, Meinzer A et al (2011) Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 80:1205–1213PubMedCrossRef

38.

Zou Y, Cheng C, Omura-Minamisawa M et al (2010) The suppression of hypoxia-inducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids. J Radiat Res ss51:47–55CrossRef

Titel: Prognostic value of HIF-1α expression during fractionated irradiation
verfasst von: L. Helbig
A. Yaromina
S.N. Sriramareddy
S. Böke
L. Koi
H. D. Thames
M. Baumann
Prof. Dr. D. Zips
Publikationsdatum: 01.11.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 11/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0150-z

Springer Medizin

Prognostic value of HIF-1α expression during fractionated irradiation